<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="150535">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01140516</url>
  </required_header>
  <id_info>
    <org_study_id>ALPHA</org_study_id>
    <nct_id>NCT01140516</nct_id>
  </id_info>
  <brief_title>Effectiveness of Antibiotics Versus Placebo to Treat Antenatal Hydronephrosis</brief_title>
  <acronym>ALPHA</acronym>
  <official_title>Antibiotic prophyLaxis Versus Placebo in Infants Diagnosed With Hydronephrosis Antenatally</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Physicians' Services Incorporated Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McMaster Surgical Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study focuses on the relationship between prophylaxis antibiotics and frequency of
      urinary tract infection in children diagnosed with antenatal hydronephrosis. Hydronephrosis
      is the most common fetal abnormality occurring in 1-5% of all pregnancies. Currently, with
      the widespread accessibility of antenatal ultrasound across cities in Ontario, the detection
      of hydronephrosis has become even more common. As a result, thousands of infants with
      hydronephrosis have been seen and managed by pediatricians, pediatric nephrologists,
      pediatric urologists, and family physicians. The investigators need to determine if
      antibiotic prophylaxis is effective in reducing the number of urinary tract infections in
      this population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine whether antibiotics (ATB) prophylaxis prevents urinary tract infection (UTI) in infants with antenatal hydronephrosis (AHN).</measure>
    <time_frame>The outcome measures will be assessed at 12 months</time_frame>
    <description>Determine the rate and frequence of UTI infection</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Hydronephrosis</condition>
  <condition>Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>Trimethoprim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prophylactic Antibiotics</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simple syrup</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim</intervention_name>
    <description>2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.</description>
    <arm_group_label>Trimethoprim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Simple Syrup</intervention_name>
    <description>2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.</description>
    <arm_group_label>Simple syrup</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Infants with AHN (one to seven months of age) confirmed postnatally with
             renal-bladder ultrasound and/or a dilated ureter â‰¥ 7mm

          2. SFU grade III and IV AHN (high grade hydronephrosis)

          3. Patients without grades II to V VUR determined by voiding cystogram (includes
             UPJO-like and primary megaureter (hydroureteronephrosis) only);

          4. Parent or legal guardian able to give free and informed consent

        Exclusion Criteria:

          1. Infants with grades II to V VUR

          2. Infants with posterior urethral valves or Prune-Belly syndrome

          3. Duplication anomalies (ureteroceles, ectopic ureters)

          4. Other conditions that may require chronic use of antibiotics

          5. Previous renal failure

          6. Allergy to trimethoprim

          7. Co-enrollment in another intervention trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>7 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis H Braga, MD, MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster Medical Centre, McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luis Braga, MD</last_name>
    <phone>905-521-2100</phone>
    <phone_ext>73777</phone_ext>
    <email>lhpbraga@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bethany Easterbrook, BSc, MSc(c)</last_name>
    <phone>905-521-2100</phone>
    <phone_ext>76692</phone_ext>
    <email>easterb@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>McMaster Children's Hospital</name>
      <address>
        <city>Hamitlon</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis H Braga, MD, MSc, PhD</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>73777</phone_ext>
      <email>lhpbraga@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Bethany Easterbrook, B. Kin</last_name>
      <phone>905-521-2100</phone>
      <phone_ext>76692</phone_ext>
      <email>easterb@mcmaster.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jorge DeMaria, FRCS(c) FAAP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Forough Farrokhyar, MPhil, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucy Giglia, MSc MD FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natasha Brownrigg, RN, MN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martha B Fulford, MSc MD FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis H Braga, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mandy Rickard, RN, MN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sick Kids Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norman Rosenblum, MD</last_name>
      <phone>(416) 813-7654</phone>
      <phone_ext>305667</phone_ext>
      <email>norman.rosenblum@sickkids.ca</email>
    </contact>
    <contact_backup>
      <last_name>Theresa Thompson</last_name>
      <phone>(416) 813-5829</phone>
      <email>theresa.thompson@sickkids.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Armando J Lorenzo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Norman Rosenblum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://fhs.mcmaster.ca/mpsrc/</url>
    <description>McMaster Pediatric Surgery Research Collaborative</description>
  </link>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 21, 2016</lastchanged_date>
  <firstreceived_date>June 8, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antenatal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Hydronephrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
